​

Trevi Therapeutics (TRVI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TRVI Stock Forecast

Trevi Therapeutics (TRVI) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $19.67, with a high of $24.00 and a low of $16.00. This represents a 49.24% increase from the last price of $13.18.

- $5 $10 $15 $20 $25 High: $24 Avg: $19.67 Low: $16 Last Closed Price: $13.18

TRVI Stock Rating

Trevi Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 1 Strong Buy (6.67%), 14 Buy (93.33%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 14 1 Strong Sell Sell Hold Buy Strong Buy

TRVI Price Target Upside V Benchmarks

TypeNameUpside
StockTrevi Therapeutics49.24%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts333
Avg Price Target$19.67$19.67$19.67
Last Closing Price$13.18$13.18$13.18
Upside/Downside49.24%49.24%49.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2519---10
Nov, 2528---10
Oct, 2528---10
Sep, 2528---10
Aug, 2528---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 19, 2025Roanna RuizLeerink Partners$16.00$11.3141.47%21.40%
Nov 14, 2025Judah FrommerMorgan Stanley$19.00$11.6862.67%44.16%
Nov 14, 2025Leland GershallOppenheimer$24.00$11.80103.39%82.09%
Oct 22, 2024Oren LivnatH.C. Wainwright$6.00$3.3579.10%-54.48%
Oct 04, 2024Mayank MamtaniB.Riley Financial$6.00$3.0298.68%-54.48%
Jul 09, 2022Leland GershallOppenheimer$12.00$3.95203.80%-8.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 19, 2025Leerink PartnersOutperformOutperformhold
Nov 14, 2025Morgan StanleyOverweightOverweighthold
Nov 14, 2025Cantor FitzgeraldOverweightOverweighthold
Nov 14, 2025OppenheimerOutperformOutperformhold
Jun 02, 2025OppenheimerOutperformOutperformhold
May 28, 2025H.C. WainwrightBuyBuyinitialise
Mar 19, 2025B. RileyBuyBuyhold
Oct 22, 2024H.C. WainwrightBuyBuyhold
Aug 30, 2024Raymond JamesOutperforminitialise
Aug 30, 2024H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.29$-0.47----
Avg Forecast$-0.31$-0.48$-0.49$-0.53$-0.53$0.02
High Forecast$-0.30$-0.46$-0.39$-0.27$-0.20$0.02
Low Forecast$-0.31$-0.49$-0.56$-0.78$-0.80$0.02
Surprise %-6.45%-2.08%----

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$1.10M$4.17M$98.09M
High Forecast---$1.10M$4.22M$98.09M
Low Forecast---$1.10M$4.12M$98.09M
Surprise %------

Net Income Forecast

$-80M $-63M $-46M $-29M $-12M $5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-29.07M$-47.91M----
Avg Forecast$-30.21M$-47.50M$-47.05M$-65.00M$-65.45M$1.61M
High Forecast$-29.23M$-46.03M$-38.41M$-26.87M$-19.70M$1.61M
Low Forecast$-31.18M$-48.97M$-55.69M$-77.40M$-78.82M$1.61M
Surprise %-3.77%0.86%----

TRVI Forecast FAQ

Is Trevi Therapeutics stock a buy?

Trevi Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 14 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Trevi Therapeutics is a favorable investment for most analysts.

What is Trevi Therapeutics's price target?

Trevi Therapeutics's price target, set by 15 Wall Street analysts, averages $19.67 over the next 12 months. The price target range spans from $16 at the low end to $24 at the high end, suggesting a potential 49.24% change from the previous closing price of $13.18.

How does Trevi Therapeutics stock forecast compare to its benchmarks?

Trevi Therapeutics's stock forecast shows a 49.24% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Trevi Therapeutics over the past three months?

  • December 2025: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Trevi Therapeutics’s EPS forecast?

Trevi Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.49, marking a 4.26% increase from the reported $-0.47 in 2024. Estimates for the following years are $-0.53 in 2026, $-0.53 in 2027, and $0.02 in 2028.

What is Trevi Therapeutics’s revenue forecast?

Trevi Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $1.1M, followed by $4.17M for 2027, and $98.09M for 2028.

What is Trevi Therapeutics’s net income forecast?

Trevi Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-47.051M, representing a -1.80% decrease from the reported $-47.911M in 2024. Projections indicate $-64.995M in 2026, $-65.451M in 2027, and $1.61M in 2028.